Background. Enterotoxigenic Escherichia coli (ETEC) is a globally prevalent cause of diarrhea. Though usually self-limited, it can be severe and debilitating. Little is known about the host transcriptional response to infection. We report the first gene expression analysis of the human host response to experimental challenge with ETEC.
Enterotoxigenic Escherichia coli (ETEC) is a common cause of diarrhea worldwide, especially in children and travelers. However, it is difficult to clinically distinguish from other causes of diarrhea, and diagnostic testing is limited in ETEC-prevalent areas. The majority of infections are self-limited though secondary dehydration can be lethal. Despite its prevalence, little is known about the host response to ETEC infection. Knowledge of the mechanisms behind clinical variability could assist in diagnosis, treatment, and prevention, because no clinically effective vaccine has been developed.
One approach to understand host-pathogen interactions is through a human challenge model. Although animal models facilitate the study of human disease, the ETEC strains that infect humans are not pathogenic in animals [1] . Consequently, human challenge studies have been the primary mechanism of studying human ETEC disease, which have revealed the dose dependence of symptoms, clinical variability between strains, and clinical course of infection [1, 2] . ETEC challenge studies have also been used to evaluate vaccine candidates and other treatments. Other pathogen challenge experiments have generated insights into the host response to infection. For example, human challenge with respiratory viruses have characterized gene expression changes that led to the development of a diagnostic signature [3] .
Based on these prior successes, we performed a human ETEC challenge to study the transcriptomic response. Not all subjects became sick, allowing a comparison of symptomatic subjects to their own baseline and to asymptomatic subjects. Moreover, differences in baseline gene expression may reveal host factors conferring resilience to infection in asymptomatic individuals. This study design also facilitates a drug repositioning analysis whereby known drug-induced gene expression changes can be matched to the ETEC-induced response, identifying potential therapeutic targets.
Subjects were admitted to the Johns Hopkins Bayview Medical Center, Center for Immunization Research inpatient unit. A stool sample was screened for infection at admission. Subjects were orally administered ETEC strain H10407 (O78:H11; colonization factor antigen [CFA]/I, labile toxin [LT] + stable toxin [ST] + ) in a bicarbonate solution, with random assignment to a dose of either 1 × 10 5 or 1 × 10 6 colony-forming units, lower than described elsewhere [4] . This previously used strain is considered more virulent than other strains in the challenge model [1] . Blood was collected in PAXgene Blood RNA tubes (PreAnalytiX) early after ETEC challenge (8 hours) , defining the baseline for this analysis. Subjects were monitored for approximately 8 days. Blood was collected, and symptoms were assessed daily. Ciprofloxacin was initiated on day 5 or sooner for severe symptoms.
Case Definitions
Patient-reported symptoms and stool output were recorded daily as described elsewhere [4] . Diarrhea was defined as 1 loose or liquid stool >300 g (grade 3 or greater) or >2 loose or liquid stools >200 g in any 48-hour period within 120 hours of ETEC challenge. Moderate-to-severe diarrhea was defined as ≥4 (or >400 g total) grade 3-5 stools in a 24-hour period.
Microarray Analysis
Total RNA was extracted from human blood using the PAXgene Blood miRNA Kit (Qiagen), according to the manufacturer's protocol. RNA quantity and quality were assessed using the Nanodrop spectrophotometer (ThermoScientific) and Agilent 2100 Bioanalyzer (Agilent), respectively. Hybridization and data collection were performed at Expression using the GeneChip Human Genome U133A2.0 Array (Affymetrix), according to the Affymetrix technical manual. Microarray data were Robust Multi-array Average normalized.
Statistical Methods
Bayesian factor regression modeling [5] was used to model correlation structure in the expression data. This served as a dimension-reduction step in which 20 000 gene expression measurements were expressed as 78 factors, each of which summarizes the expression of correlated genes into a single score. Each factor contains a variable number of genes, and any gene may be present in multiple factors. This analytic strategy has been used effectively in other challenge and gene expression studies [3] . The method is unsupervised (ie, does not use phenotype labels). A linear mixed model was used to compare symptomatic profiles and asymptomatic profiles over time. An analysisof-covariance model, accounting for each subject's baseline gene expression, was used to study differences at the time of peak symptoms. A Benjamini-Hochberg false discovery rate (FDR) <10% accounted for multiple comparisons. Analysis was conducted using R 3.1 software (R Foundation for Statistical Computing, Vienna, Austria; available at: http://www.r-project.org/) [6, 7] .
The limma method [8] was used to detect genes whose baseline difference persisted throughout the time course. A mixed model accounted for correlations within subjects and the limma empirical-Bayes method used information across genes for variance estimation. Genes with an FDR <5% were considered significant.
Functional Annotation
We used BioMart software (available at: http://www.biomart. org/) [9] to map probe set identifiers to HGNC gene symbols using the Homo sapiens GRCh38.p2 data set. DAVID 6.7 software (National Institutes of Health, Bethesda, MD; available at: http://david.ncifcrf.gov/) [10] was used for functional annotation. The gene ontology (GO) data sets queried included biological processes, cellular components, and molecular functions. Significance was defined at an FDR of <10%. Figure 1 . Experimental design. A, Thirty healthy subjects were randomly assigned to an enterotoxigenic Escherichia coli dose of either 1 × 10 5 or 1 × 10 6 colonyforming units (CFUs). Of the 15 subjects assigned to receive 1 × 10 5 CFUs, 2 became symptomatic and 13 remained asymptomatic. Of the 15 assigned to receive 1 × 10 6 CFUs, 4 became symptomatic and 11 remained asymptomatic. In all, 6 subjects had severe symptoms, and 24 remained asymptomatic. For analyses comparing symptomatic and asymptomatic subjects, only 6 asymptomatic subjects were included. B, The symptomatic response signature compared symptomatic subjects at the time of peak symptoms (which varied from day 2 to day 4) to their baseline (8 hours after challenge). The peak comparison compared symptomatic subjects at the time of peak symptoms with matched time points in asymptomatic subjects. The longitudinal comparison and resilience signature were derived from comparing all time points in symptomatic subjects with all time points in asymptomatic subjects.
RESULTS

Research Subjects
Subjects were randomly assigned to 2 challenge doses. Two of 15 subjects had severe symptoms at 1 × 10 5 colony-forming units, and 4 of 15 subjects at 1 × 10 6 colony-forming units ( Figure 1A ). All 6 subjects (3 female, 3 male) with severe symptoms underwent gene expression analysis, along with 6 asymptomatic subjects (1 female, 5 male). We matched for sex where possible, but only 1 asymptomatic female was available as a control. Peak symptoms occurred 2-4 days after challenge, and all 12 subjects demonstrated shedding of ETEC in stool at some point during the study (Figure 2 ; Supplementary Figure 1 ). Before challenge, subjects were screened for preexisting antibodies including lipopolysaccharide immunoglobulin (Ig) A and IgG, heat-labile toxin B (LTB) IgA and IgG, and CFA/I IgA and IgG. There were no significant differences in titer between symptomatic and asymptomatic subjects except for LTB IgG, for which asymptomatic subjects had higher levels (P = .04; 95% confidence interval, −502.9 to −9.849 ELISA units). However, these differences were unlikely to have affected symptom status, given the lack of protection conferred by such antibodies [11, 12] .
Host Response in Symptomatic Infection
To characterize the host response to ETEC infection, we compared the gene expression of symptomatic subjects (n = 6) at peak symptoms compared with baseline (symptomatic response signature). Of the factors identified, 19 of 78 achieved significance at 10% FDR. We then defined the 1551 probe sets represented within these 19 factors. Although 19 factors achieved significance, not all 1551 probe sets did. Probe sets are grouped into factors because of their correlation with each other and not necessarily with the ETEC response. Thus, each probe set was analyzed for individual significance. Only 403 of 1551 probe sets achieved significance when comparing peak symptom to baseline gene expression (Supplementary Table 1 ).
These 403 probe sets mapped to 406 unique genes. Of the 403 probe sets, 152 were up-regulated and 251 were down-regulated at the time of peak symptoms. Functional annotation of the 152 up-regulated probe sets identified 7 GO categories (10% FDR) including vacuole biology and immune response ( Table 1) . Functional annotation of the 251 down-regulated probe sets identified 3 GO categories (10% FDR) ( Table 1) .
Symptomatic Versus Asymptomatic Comparison
Whereas all subjects were challenged with ETEC and shed the bacteria during the experiment, symptoms developed in only 6 of 12. To characterize the changes in gene expression between these 2 groups, 2 comparisons were used ( Figure 1B ). The first approach compared symptomatic subjects at peak symptoms to a corresponding time point in asymptomatic subjects ( peak comparison), adjusted for each subject's own baseline gene expression. This comparison captures the changes in gene expression associated with symptomatic disease. In the peak comparison, 9 factors (822 probe sets) achieved significance. Of those 822 probe sets, 160 (118 up-regulated and 42 downregulated) achieved individual significance (P < .05; Supplementary Table 2 ), mapping to 156 genes.
The second approach compared symptomatic and asymptomatic subjects over the entire 7-day study (longitudinal comparison). This approach captured differences that may have been present at times other than peak symptoms ( Figure 3 offers an example). Fourteen factors (1014 probe sets) achieved significance. Of these 1014 probe sets, 137 achieved individual significance (P < .05; Supplementary Table 3 ), mapping to 135 genes. Of these 14 factors, 5 were also significant in the peak comparison (factors 1, 14, 29, 44, and 76). Factor 76 was most significant in both peak and longitudinal comparisons ( Figure 4 ). Of the genes significant in factor 76, ICAM1 is related to the class I major histocompatibility complex (MHC) pathway [13] , and ADM encodes a protein with antibacterial activity against E. coli [14] .
Combining the results from both comparisons maximized our ability to discriminate gene expression differences while maintaining statistical rigor. This resulted in 265 probe sets mapping to 254 unique genes. Functional annotation of the 265 probe sets resulted in 16 statistically significant GO categories, highlighting various aspects of the immune response (Table 1) .
Resilience to Infection
To further characterize the difference between asymptomatic and symptomatic subjects, we hypothesized that host factors confer resilience to symptomatic infection. To test this hypothesis, we identified gene expression differences between susceptible (symptomatic) and resilient (asymptomatic) subjects that were detectable at baseline. Sex was included as a covariate given the mismatch between groups. Twenty-six probe sets mapping to 29 genes were statistically significant (5% FDR). Half were up-regulated in resilient compared with susceptible subjects (Figure 5 , Supplementary Table 4 ).
Even at a 5% FDR, these genes may represent spurious associations. We therefore evaluated their biological plausibility in conferring resilience to infection. VarElect [13] uses GeneCards databases to associate genes with phenotypes of interest. We used VarElect to find links between the resilience signature and the "Escherichia coli" and "infection" phenotypes. Seven genes were directly linked to the E. coli phenotype, whereas the majority of remaining genes were indirectly related. Fifteen genes were directly related to the infection phenotype, including 6 of 7 related to the E. coli phenotype. These 6 genes fell into 2 groups: C4BPA (down-regulated in resilience) and 5 tubulin genes (up-regulated in resilience). C4BPA inhibits the classic complement pathway, and tubulins are involved in E. coli infection pathogenesis. Other genes directly related to the infection phenotype included GZMH and TAP2. WARS was associated with the E. coli phenotype. Functional annotation of the 13 down-regulated probe sets in resilient subjects identified no statistically significant GO categories, whereas the 13 up-regulated probe sets were enriched for genes in the MHC protein binding and MHC class I protein binding pathways (Table 1) .
Drug Repositioning Analysis
The Broad Connectivity Map database [15] (Connectivity Map build 02) describes gene expression changes induced in human cell lines by 6100 perturbagens (small bioactive molecules). We hypothesized that comparing ETEC-induced changes to Table 2) to identify perturbagens of interest. Among the most significant correlations were protein synthesis inhibitors (anisomycin and puromycin). Typical antipsychotics (thioridazine, fluphenazine, trifluoperazine, prochlorperazine, and perphenazine) and piperacetazine, an antipsychotic prodrug, were also significantly correlated with ETEC-induced changes. Zinc biology was represented by vorinostat and trichostatin A, histone deacetylase inhibitors that chelate zinc. 15-Δ-Prostaglandin J 2 [16] and withaferin A [17] inhibit the NF-κB pathway. Antibacterials were also identified, including cephalexin and amoxicillin with negative and rifampicin and metronidazole with positive enrichment scores.
DISCUSSION
Gene Expression Profiling
Although many details of ETEC pathogenesis are known, ours is the first study defining associated changes in peripheral blood gene expression. This analysis has identified gene expression differences at baseline that discriminate subjects in whom symptomatic ETEC infection develops from those who remain asymptomatic, revealing potential mechanisms of resilience to infection.
Many of the genes identified through our analyses have previously been identified in the host response to infection. DHRS9, FCER1G, EMR1, CEACAM1, and CD177 were identified in a comparison of systemic inflammatory response syndrome and sepsis [18] though not always in the same direction of change as observed in this challenge. MS4A4A, FEN1, SERPING1, OAS1, MCM6, and GINS2 were notably dysregulated in the host response to influenza A [3, 19] . OAS1, up-regulated in symptomatic subjects with ETEC, encodes an RNase that is part of the innate immune response to viral infection [14] , raising the possibility of an immunoprotective role in bacterial or toxin-producing infections. SERPING1, also up-regulated in symptomatic subjects Figure 3 . Longitudinal expression profile of factor 59. Shaded region indicates model mean and 95% confidence interval for each cohort. This is an example of a factor that was included in the longitudinal comparison (P = .02; adjusted for Benjamini-Hochberg false discovery rate [FDR]) but not the peak comparison (P = .32; FDR adjusted). The factor scores, representing gene expression, of both cohorts was comparable at the time of peak symptoms (varying by subject between days 2 and 4), and the difference in factor scores was greater at day 1 and day 7. Abbreviations: Asx, asymptomatic; Sx, symptomatic. with ETEC, inhibits the complement cascade [14] . Considering that ETEC is a toxin-mediated infection, the role of complement in ETEC is less obvious. However, C5a has proinflammatory properties, directly stimulating interleukin 6 production from colonic epithelial cells in a murine Citrobacter rodentium infection, which mimics human enteric E. coli infections [20] .
Twenty-five genes from our analyses were also identified in a comparison of pediatric host response to invasive E. coli versus Streptococcus pneumoniae infection [19] . Many of these genes more strongly associated with the S. pneumoniae response than with nongastrointestinal E. coli infection. The reasons for these differences are unclear. On the surface, one might assume that different E. coli pathovars induce similar host responses. However, both ETEC and S. pneumoniae cause disease in sites of frequent colonization: the intestine and respiratory tract, respectively. As such, the nature of their host-pathogen interactions are likely to be more similar than ETEC is to invasive E. coli infection.
This finding relates to one of the limitations in this study: We measured peripheral blood cell gene expression and not intestinal mucosal gene expression, which could not be obtained for safety reasons. Although we are unable to directly correlate gene expression in blood with intestinal mucosa, there are published data to suggest correlations are high, including in pigs, which are prone to postweaning ETEC-related gastroenteritis [21, 22] . In contrast to this human challenge, porcine challenges have largely focused on the mucosal response although some describe correlations between peripheral blood or lymphoid tissue and mucosal biology. For example, the increased number of CD3 + CD4 + CD8 − T cells in the peripheral blood mirrored changes seen in small intestinal lamina propria [23] . Gene expression of many immune-related genes were equivalent in jejunal lamina propria and Peyer patches, from which immune cells are expected to enter into the peripheral circulation [24] . Proinflammatory cytokines, such as those implicated in this human ETEC challenge, were highly correlated in the peripheral blood and intestinal mucosa of ETEC-challenged pigs, further supporting the hypothesis that peripheral blood provides a useful correlate of tissue-specific changes [25] . In addition to ETEC infection, several studies revealed high correlation between mucosal and peripheral blood gene expression in human subjects with inflammatory bowel disease [26] [27] [28] .
Drug repositioning identified candidates for further investigation, as well as novel mechanisms of pathogenesis. For example, the protein synthesis inhibitors anisomycin and puromycin induce gene expression changes in vitro similar to what is seen with ETEC infection, and both are produced by Streptomyces bacterial species. This suggests host protein synthesis inhibition is a part of ETEC pathogenesis as anisomycin does not have activity against E. coli [29] . Several antipsychotic drugs, which induce anti-inflammatory cytokine secretion and suppress proinflammatory cytokines [30] , correlated with ETEC infection. This is consistent either with an ETEC-derived virulence mechanism or with attempts by the host to temper the inflammatory response. Tanespimycin, an antitumor antibiotic and Hsp90 inhibitor, was also identified as significant. ETEC increases TLR4 expression, whose function depends on Hsp90 [31] . Hsp90 inhibitors have also been investigated as therapeutics in intestinal parasitic diseases [32] .
Symptomatic subjects demonstrated gene expression changes similar to those observed with NF-κB pathway inhibitors, a pathway associated with the ETEC response [33] . Another related pathway tied to ETEC pathogenesis is ubiquitination [34] . Withaferin A, significant in the repositioning analysis, is thought to inhibit NF-κB by inhibiting the ubiquitin-mediated proteasome pathway [17] . Although not classically associated with ETEC, type III secretion systems expressed by enteropathogenic and enterohemorrhagic E. coli inhibit host immune pathways, including NF-κB [35] .
Zinc biology was prominent in the drug repositioning analysis. Vorinostat and trichostatin are histone deacetylase inhibitors that A negative enrichment score indicates an opposite direction. The magnitude of the score indicates the degree of similarity between the perturbagen-induced and enterotoxigenic E. coli-induced signatures. Some perturbagens may be listed more than once if they were significant in both the symptomatic response signature and the peak comparison.
chelate zinc [36] . Zinc enhanced innate immunity to ETEC in children, increasing complement C3 levels, enhancing phagocytic activity, and increasing the naive-memory T-cell ratio [37] . In a pig model, zinc supplementation decreased immune-response gene expression as well as expression of MUC4, a proposed ETEC K88 receptor [24] . Cephalexin is an antibiotic that can be used to treat ETEC infection. In the drug repositioning analysis, cephalexin had a negative enrichment score, suggesting possible symptom-mitigating effects on the host independent of direct antibacterial activity. Amoxicillin revealed similar associations. In contrast, rifampicin had a positive enrichment score, suggesting a potential immune augmentation benefit to the host, in addition to direct antibacterial activity. In light of the emergence of drug-resistant ETEC [38] and antibacterial resistance in general, therapeutic benefits achieved through host effects may become increasingly important.
Human host susceptibility to enteric infections has recently been described for norovirus and rotavirus, derived from polymorphisms in the FUT2 gene, which represent the histo-blood group antigens to which both viruses bind [39] . Moreover, asymptomatic shedding of norovirus in outbreak situations has also been described, further supporting the importance of host factors in determining whether a given exposure results in disease [40] . In this study, we identified potential host susceptibility factors without a priori assumptions regarding their mechanisms. In doing so, we identified 29 genes differentially expressed at baseline that discriminated between symptomatic and asymptomatic individuals, suggesting innate resilience to ETEC infection. This finding offers insights into the biology of infection resilience, as well as potential targets for prognostic testing and therapeutic development. We acknowledge the potential for overfitting, making such discoveries potentially spurious. However, there is ample support for many of these genes playing a role in resilience. For example, C4BPA inhibits the classic complement pathway and is bound by a K1 E. coli strain outer membrane protein to evade complement-mediated destruction [41] . Its downregulation in resilient subjects suggests an important role for complement activation in ETEC clearance. GZMH, up-regulated in resilient subjects, has antiviral proteolytic activity [42] and may also play a role in ETEC resilience.
Interestingly, Sutai pigs have variable ETEC infection susceptibility attributed in part to variable E. coli F18 adhesion [43] , TAP1 genotype [44] , and IMTGP, an E. coli K88 receptor [45] . Although these specific genes and mechanisms were not identified in this study, we did note some overlap between porcine and human ETEC resistance mechanisms. For example, CD8A, part of the class I MHC pathway, was up-regulated in ETEC-resilient subjects as it was in resilient pigs. SLA-1 and SLA-3, both involved in MHC antigen presentation, were also differentially expressed between sensitive and resistant pigs [21] . At the pathway level, immune and leukocyte activation were important to pig resilience. Although these pathways were not specifically enriched for in this human resilience signature, they were significant in the comparison of symptomatic versus asymptomatic subjects. Some of the 29 resilience genes have also been identified in other infection-related gene expression studies. Similar to what we observed with ETEC, LGALS8, TAP2, and WARS were upregulated in an influenza challenge experiment among subjects with more severe symptoms [46] . WARS was expressed at a higher level in patients with active versus latent tuberculosis [47] . In a Haemophilus ducreyi challenge study, LGALS8, TAP2, and CD8A were expressed at a higher level in subjects who became infected compared with those who did not, despite prior pathogen exposure [48] . We also found supportive evidence in an influenza vaccination model, hypothesizing that vaccination imparts resilience. MXRA7 and RNF187 showed similar expression changes in ETEC-susceptible subjects as in a prevaccination cohort (vs post-vaccination) [49] . Although these studies support the hypothesis that host resilience to infectious disease is detectable in the baseline healthy state, validation at a population scale or through functional experimentation would lend further support.
Limitations
This study included a small number of subjects, which limits generalizability. Nevertheless, the abundance of statistically significant and biologically plausible differences highlight the host response to ETEC challenge. Children bear the highest disease burden from ETEC but were not represented in this challenge. Although it cannot be assumed the pediatric and adult responses to ETEC are the same, their host responses are similar in other infectious diseases [3, 50] . Another caveat is that we measured peripheral blood gene expression and used this as a surrogate for the mucosal/intestinal host response. Although they are likely to be highly correlated, there are also likely to be differences. Lastly, the resilience signature was identified with the baseline measure obtained 8 hours after challenge. Although few changes are likely to be occurring this quickly based on other challenge experiments [3] , the resilience gene expression signature may instead reflect an early, differential host response conferring resilience, rather than an innate biology.
Conclusions
This study is the first to describe statistically significant and biologically plausible differences in host gene expression induced by ETEC infection. Further, the differential expression of some genes at baseline may confer resilience to infection. These findings offer a baseline understanding of host response in gastrointestinal infection, which can serve as a basis for the study of other infectious diseases as well as noninfectious gastrointestinal disease. materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.
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